

CSTE Core Group Meeting (7/11)

Agenda:

- Introductions (Name, Organization/Title, CMV work, Worked on a position statement before?)
- Meredith (CSTE): Overview of Position Statement process and timeline
 - Authorship expectations and requirements
 - SME expectations and requirements
- Ottawa - who will be attending from the working group? Happy hour/dinner?
 - Stephanie will create/share list of group members' presentations
- For future meetings, brainstorm the following questions:
 - What is the need for a case definition at this time?
 - Anyone want to present data at future WG meetings? CSTE VPD subcommittee fall meeting?

Attendees:

Kristen M. Nichols Heitman – CDC Lead

Sandra Roush – CDC, CSELS NNDSS, worked with position statements

Breanna Pennings – CDC, Health Scientist, works with sandy Roush, first time on a position statement

Amelia Blumberg – CSTE, program analyst on ID team, VPD subcommittee, helps to support position statements

Van T. Tong – CDC, NCBDDD – SETNET, supporting the update for the zika case definition

Kate Woodworth – CDC, Peds MD and medical epidemiologist, NCBDDD - SETNET

Suzanne Gilboa – Not Present

Scott Grosse – CDC, Health Economist, reviewed position statements

Gail J. Demmler – Baylor College of Medicine, national cCMV registry development – previous work in case definition, worked on a variety of position statements

Albert Park – Primary Children's Hospital, Utah, MD/Otolaryngologist, currently working on CMV position statement with AAP

David Kimberlin – University of Alabama, conducted multicenter antiviral studies, neonatal herpes and covid position statement

Angela G. Shoup – Professor at University of Texas at Dallas

Karen Fowler – University of Alabama, EPI, studies infant and maternal CMV infections, behavioral prevention, collaborated on Rawlinson cCMV consensus statement

Pablo Sanchez – Neonatologist works with pediatric diseases, worked on a few position statements – congenital syphilis, been involved in cCMV studies since 1990s, currently looking at biosignatures of CMV to identify predictors of hearing loss

Mark Schleiss – University of MN, Peds, worked on Rawlinson consensus statement

Megan Pesch – Not Present

Stephanie McVicar – Utah Lead

Max Sidesinger - Utah Lead

Tatiana M. Lanzieri – CDC Lead

Kelley Raines -CDC Lead

Jane Fornoff – DPH IL, EPI and data manager APORS, not been a part of position statement

Ginger Mullin – DPH IL, Audiologist, no position statement work

Kimberly Piper – IA DPH, Executive officer, oversees state newborn screening program, looking to establish cCMV surveillance, not participated in position statement

Paul Romitti - Not Present - **Kristen Conway** sat in

Tammy O'Hollearn – IA DPH, Director of NBS, have not worked on a position statement

Kirsten Coverstone – MN DPH, Audiologist, have worked on a position statement before

Sondra Rosendahl – MN DPH, genetic counselor, coordinate newborn screening program, implementing universal screening

Tory Kaye - Not Present

Chas DeBolt – WA DPHH, VPD subject matter expert, co-chair of VPD subcommittee at CSTE, primary author for several position statements

Meredith Lichtenstein – Oversees CSTE policy and position statement process, supported 80+ position statements

Ashrita Rau – CDC, New fellow with CMV program

Sara Bowman – SD DPH, VPD epi, no position statement work, do not currently conduct cCMV surv but hope to do so in future

Notes:

- Stephanie gave introduction
- Introductions of Everyone on the Call (see above)
- Meredith Lichtenstein and Amelia Blumberg – CSTE Position Statement Overview (See slides)
 - CSTE History
 - Annual Process Overview – outline in CSTE bi-laws
 - Only a public health case definition NOT intended for clinical use
 - Nationally Notifiable Recommendations – We are not currently proposing
 - Steps of Process:
 - Development – Fall/Winter
 - Submission – spring of each year, 13 weeks prior to CSTE conference (we will follow traditional time line)
 - Approval – 3 levels of approvals
 - CSTE Executive Board
 - All active members (at annual conference)
 - Council (vote from each state/territory)
 - Finalization – technical review, approved statements posted on CSTE
 - Implementation – January 1st of following year, states can implement sooner if they choose
 - 2023 Timeline for Position Statement
 - Submissions due 3/30/2023
 - Revised submissions due 5/11/2023
 - Final revisions due 6/22/2023
 - Authors Vs SMES vs Partners
 - Authors – must be CSTE member
 - Submitting/presenting author – must be active member of CSTE

- Each author must look at each of their organization requirements
- SME consultants – do not have to be CSTE members
 - Allowed access to member only content
 - Can participate/actively participate in presentation of position statement
 - Advise on content
 - Head SME – CDC programmatic point of contact
- Partners
 - APHL
 - Can send position statements for a response or FYI
 - CDC is always listed as an agency
- Responsibilities of Submitting Author, Co-authors, and SME(s)
 - Before submission
 - After submission, before annual conference
 - During Annual Conference (Salt Lake City, 2023)
 - Post conference
- Tips
 - Development is iterative process
 - Document discussions that lead to important decisions
 - Don't wait until the end to complete the technical supplement
 - Don't forget to rely on each other
 - Don't wait to ask for help (positionstatements@cste.org, mlichtenstein@cste.org)
- Stephanie will email out list of those presenting in Ottawa in Core WG
 - Would like to do happy hour, lunch, or dinner, if anyone interested
- For future meetings, brainstorm the following questions:
 - What is the need for a case definition at this time?
 - Anyone want to present data at future WG meetings? CSTE VPD subcommittee fall meeting?
- Plan on meeting monthly; Doodle polls will be sent